These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
215 related articles for article (PubMed ID: 17579511)
41. Survey of vaccine distribution and delivery issues in the USA: from pediatrics to pandemics. Jacobson SH; Sewell EC; Jokela JA Expert Rev Vaccines; 2007 Dec; 6(6):981-90. PubMed ID: 18377360 [TBL] [Abstract][Full Text] [Related]
42. Vaccine preventable diseases and vaccination coverage in Aboriginal and Torres Strait Islander people, Australia 2003 to 2006. Menzies R; Turnour C; Chiu C; McIntyre P Commun Dis Intell Q Rep; 2008 Jun; 32 Suppl():S2-67. PubMed ID: 18711998 [TBL] [Abstract][Full Text] [Related]
43. Aflunov(®): a prepandemic influenza vaccine. Gasparini R; Amicizia D; Lai PL; Panatto D Expert Rev Vaccines; 2012 Feb; 11(2):145-57. PubMed ID: 22309663 [TBL] [Abstract][Full Text] [Related]
44. Immunogenicity and tolerability of an MF59-adjuvanted, egg-derived, A/H1N1 pandemic influenza vaccine in children 6-35 months of age. Knuf M; Leroux-Roels G; Rümke HC; Abarca K; Rivera L; Lattanzi M; Pedotti P; Arora A; Kieninger-Baum D; Della Cioppa G Pediatr Infect Dis J; 2014 Dec; 33(12):e320-9. PubMed ID: 24978857 [TBL] [Abstract][Full Text] [Related]
45. Seasonal and pandemic influenza: a 2007 update on challenges and solutions. Monto AS; Whitley RJ Clin Infect Dis; 2008 Apr; 46(7):1024-31. PubMed ID: 18444819 [TBL] [Abstract][Full Text] [Related]
46. Pandemic H5N1 influenza vaccine development: an update. El Sahly HM; Keitel WA Expert Rev Vaccines; 2008 Mar; 7(2):241-7. PubMed ID: 18324892 [TBL] [Abstract][Full Text] [Related]
47. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Nicholson KG; Colegate AE; Podda A; Stephenson I; Wood J; Ypma E; Zambon MC Lancet; 2001 Jun; 357(9272):1937-43. PubMed ID: 11425416 [TBL] [Abstract][Full Text] [Related]
48. Experimental challenge of chicken vaccinated with commercially available H5 vaccines reveals loss of protection to some highly pathogenic avian influenza H5N1 strains circulating in Hong Kong/China. Connie Leung YH; Luk G; Sia SF; Wu YO; Ho CK; Chow KC; Tang SC; Guan Y; Malik Peiris JS Vaccine; 2013 Aug; 31(35):3536-42. PubMed ID: 23791547 [TBL] [Abstract][Full Text] [Related]
49. The use of vaccination as an option for the control of avian influenza. Capua I; Marangon S Avian Pathol; 2003 Aug; 32(4):335-43. PubMed ID: 17585456 [TBL] [Abstract][Full Text] [Related]
50. Safety and immunogenicity of a 2009 pandemic influenza A H1N1 vaccine when administered alone or simultaneously with the seasonal influenza vaccine for the 2009-10 influenza season: a multicentre, randomised controlled trial. Vajo Z; Tamas F; Sinka L; Jankovics I Lancet; 2010 Jan; 375(9708):49-55. PubMed ID: 20018367 [TBL] [Abstract][Full Text] [Related]
51. Reducing the impact of the next influenza pandemic using household-based public health interventions. Wu JT; Riley S; Fraser C; Leung GM PLoS Med; 2006 Sep; 3(9):e361. PubMed ID: 16881729 [TBL] [Abstract][Full Text] [Related]
52. FDA/NIH/WHO public workshop on immune correlates of protection against influenza A viruses in support of pandemic vaccine development, Bethesda, Maryland, US, December 10-11, 2007. Eichelberger M; Golding H; Hess M; Weir J; Subbarao K; Luke CJ; Friede M; Wood D Vaccine; 2008 Aug; 26(34):4299-303. PubMed ID: 18582523 [TBL] [Abstract][Full Text] [Related]
53. Variation in loss of immunity shapes influenza epidemics and the impact of vaccination. Woolthuis RG; Wallinga J; van Boven M BMC Infect Dis; 2017 Sep; 17(1):632. PubMed ID: 28927373 [TBL] [Abstract][Full Text] [Related]
54. Evaluating the Impact of Pharmacies on Pandemic Influenza Vaccine Administration. Schwerzmann J; Graitcer SB; Jester B; Krahl D; Jernigan D; Bridges CB; Miller J Disaster Med Public Health Prep; 2017 Oct; 11(5):587-593. PubMed ID: 28219461 [TBL] [Abstract][Full Text] [Related]
55. Optimal dosing and dynamic distribution of vaccines in an influenza pandemic. Wood J; McCaw J; Becker N; Nolan T; MacIntyre CR Am J Epidemiol; 2009 Jun; 169(12):1517-24. PubMed ID: 19395691 [TBL] [Abstract][Full Text] [Related]
56. Effective, robust design of community mitigation for pandemic influenza: a systematic examination of proposed US guidance. Davey VJ; Glass RJ; Min HJ; Beyeler WE; Glass LM PLoS One; 2008 Jul; 3(7):e2606. PubMed ID: 18596963 [TBL] [Abstract][Full Text] [Related]
57. Mitigating effects of vaccination on influenza outbreaks given constraints in stockpile size and daily administration capacity. Cruz-Aponte M; McKiernan EC; Herrera-Valdez MA BMC Infect Dis; 2011 Aug; 11():207. PubMed ID: 21806800 [TBL] [Abstract][Full Text] [Related]
58. Hedging against antiviral resistance during the next influenza pandemic using small stockpiles of an alternative chemotherapy. Wu JT; Leung GM; Lipsitch M; Cooper BS; Riley S PLoS Med; 2009 May; 6(5):e1000085. PubMed ID: 19440354 [TBL] [Abstract][Full Text] [Related]
59. Prioritization of pandemic influenza vaccine: rationale and strategy for decision making. Schwartz B; Orenstein WA Curr Top Microbiol Immunol; 2009; 333():495-507. PubMed ID: 19768421 [TBL] [Abstract][Full Text] [Related]
60. Optimal vaccine allocation for the early mitigation of pandemic influenza. Matrajt L; Halloran ME; Longini IM PLoS Comput Biol; 2013; 9(3):e1002964. PubMed ID: 23555207 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]